OncoSec Medical (NASDAQ:ONCS) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of OncoSec Medical (NASDAQ:ONCSGet Rating) in a research note issued on Saturday. The firm set a “sell” rating on the biotechnology company’s stock.

ONCS has been the topic of several other reports. Zacks Investment Research raised shares of OncoSec Medical from a “sell” rating to a “hold” rating in a research note on Tuesday. BTIG Research lowered their price target on shares of OncoSec Medical from $10.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, March 16th.

OncoSec Medical stock opened at $0.77 on Friday. The stock has a market cap of $30.30 million, a P/E ratio of -0.74 and a beta of 2.03. OncoSec Medical has a 12 month low of $0.67 and a 12 month high of $4.25. The company’s fifty day simple moving average is $0.97 and its 200-day simple moving average is $1.06.

OncoSec Medical (NASDAQ:ONCSGet Rating) last released its quarterly earnings results on Tuesday, March 15th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.14). On average, research analysts anticipate that OncoSec Medical will post -0.59 earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in ONCS. Susquehanna International Group LLP lifted its position in shares of OncoSec Medical by 62.7% in the fourth quarter. Susquehanna International Group LLP now owns 44,075 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 16,990 shares in the last quarter. Geode Capital Management LLC raised its position in shares of OncoSec Medical by 7.1% in the fourth quarter. Geode Capital Management LLC now owns 262,478 shares of the biotechnology company’s stock valued at $251,000 after purchasing an additional 17,467 shares during the period. HighTower Advisors LLC bought a new position in shares of OncoSec Medical in the third quarter valued at about $45,000. Tocqueville Asset Management L.P. grew its stake in shares of OncoSec Medical by 86.8% in the third quarter. Tocqueville Asset Management L.P. now owns 49,500 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 23,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new position in shares of OncoSec Medical in the third quarter valued at about $53,000. Institutional investors own 13.98% of the company’s stock.

OncoSec Medical Company Profile (Get Rating)

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.

Further Reading

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.